U.S. stock futures plopped before the open Monday as investors faced another medley of earnings and evaluated the outlook for interest rates following January's blowout jobs report.
(Bloomberg) -- Wall Street equity futures, European stocks and bonds dropped as an unexpectedly strong US jobs report raised the prospect of more rate hikes from the Federal Reserve. Concern over US-China geopolitical tensions also weighed on sentiment.Most Read from BloombergTwin Earthquakes Kill More Than 1,000 in Turkey and SyriaChina Moves From Contrite to Confrontational Over US BalloonUS Moves to Recover Chinese Balloon While Weighing RetaliationF-22 Makes First Air-to-Air Strike in Chines
With its share price off by 11% over the past 12 months, CRISPR Therapeutics (NASDAQ: CRSP) may be down, but it's far from being out. The biotech's efforts to develop gene therapies for conditions like sickle cell disease are continuing, and there's reason to believe that success could be on the horizon. Here's why last year's stock price declines simply won't matter in the long run.